SEMA7A

Across TCGA pan-cancer cohorts, SEMA7A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEMA7A data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SEMA7A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEMA7A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and THCA are the cancer types where SEMA7A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
UCEC	OS	Median	All	1.000	0.651	.013	14	view →
THCA	OS	Median	All	0.294	0.945	<.001	8	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	8	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEMA7A–SCLC (OS)

Open the SCLC breakdown →